Cancidas

(caspofungin acetate)

ApprovedSmall molecule

Cancidas is a small molecule that works as a 1,3-Beta-Glucan Synthase Inhibitor.[2] It is being used across 4 indications, with its most advanced program in Approved.[1]

Cancidas is one of 96 small molecule programs targeting Candidemia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

CandidemiaUnknown

Fungal Infectious DiseaseUnknown

Liver TransplantActive, not recruiting

PneumoniaNot yet recruiting

CandidemiaPreclinical

Unknown

Fungal Infectious DiseasePreclinical

Unknown

Liver TransplantApproved

Active, not recruiting

PneumoniaPhase 2

Not yet recruiting

Competition

Competitive Landscape

155 competitors in Pneumonia

#DrugCompanyPhaseTrials

Cancidas

FFresenius Kabi USA, LLC

Approved

1 2

Primaquine

Sanofi

Preclinical

1 3

Acanya

Pfizer

Preclinical

1 4

Plaquenil

Jazz Pharmaceuticals

Preclinical

1 5

Avlosulfon

AAlmirall, S.A.

Preclinical

4 6

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

2 7

Advil

KKenvue Brands

Preclinical

2 8

Pepcid

KKenvue Brands

Preclinical

1 9

Aciphex

Akero Therapeutics

Preclinical

1 10

Protonix

WWyeth-Lederle Vaccines

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1/2Not yet recruiting

Pneumonia

NCT06892951

Clinical

Trials by Indication[1]

Neutropenia4 trials

A 28 - 90 Days Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Injection as Empirical Therapy in Indian Adults With Persistent Fever and Neutropenia (0991-053)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00379964·50 enrolled

Caspofungin Acetate in Treating Children With Fever and Neutropenia

Completed·NNational Cancer Institute (NCI)·N/A·NCT00020527

Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment

Completed·MMemorial Sloan Kettering Cancer Center·Phase 3·NCT00008359

Show 1 more trial

Open, Pharmacokinetic Study of Caspofungin Acetate in Immunocompromised Young Children With Febrile Neutropenia (0991-042)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00292071·16 enrolled

Pediatric Patients2 trials

Documented Candida or Aspergillus Infections in Pediatric Patients (0991-043)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00082524·50 enrolled

MK0991 Versus Amphotericin B for Empirical Therapy in Febrile, Neutropenic Pediatric Patients (0991-044)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00082537·100 enrolled

Candidiasis2 trials

A Study of Caspofungin Acetate (MK0991) for the Treatment of Esophageal Candidiasis or Invasive Candidiasis in Chinese Adults (MK-0991-066)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00635648·63 enrolled

Pilot Feasibility Study With Patients Who Are at High Risk For Developing Invasive Candidiasis in a Critical Care Setting (MK-0991-067)

Terminated· Merck & Co. logo

Merck & Co.·Phase 2·NCT01045798·15 enrolled

Pneumonia1 trial

CaspoNEB: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia

Not yet recruiting·UUniversity Hospital, Tours·Phase 1/2·NCT06892951·100 enrolled

Infants1 trial

Open, Pharmacokinetic Study of Caspofungin in Neonates and Infants (0991-058)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00330395·16 enrolled

8 more indications

Acute Myeloid Leukemia1 trial

Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia

Completed·CChildren's Oncology Group·Phase 3·NCT01307579·517 enrolled

Invasive Fungal Infections1 trial

Voriconazole and Caspofungin Acetate in Treating Invasive Fungal Infections in Patients With Weakened Immune Systems

Terminated·OOHSU Knight Cancer Institute·Phase 2·NCT00238355·13 enrolled

Aspergillosis1 trial

Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00110045·171 enrolled

Stem Cell Transplant1 trial

Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant

Completed·CChildren's Oncology Group·Phase 3·NCT01503515·292 enrolled

Fungal Infection1 trial

A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00250432·204 enrolled

Liver Transplant1 trial

To Evaluate the Efficacy and Safety of Micafungin in Preventing Invasive Mycosis After Liver Transplantation

Unknown status·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 4·NCT04728971·200 enrolled

Infections1 trial

A Clinical Study of MK0991 (Caspofungin) in Japanese Patients With Deep-seated Candida or Aspergillus Infections (0991-062)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00717860·121 enrolled

Unspecified1 trial

Empirical Versus Preemptive Antifungal Therapy

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT01288378·556 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 26, 2001

CANCIDAS

NDA NDA021227

Dec 30, 2016

CASPOFUNGIN ACETATE

NDA NDA206110

Sources

References

[1]
ClinicalTrials.gov — 18 trial records for caspofungin acetate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — caspofungin acetate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for caspofungin acetate. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA206110). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Fresenius Kabi USA, LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: 1,3-Beta-Glucan Synthase Inhibitor[2]
Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: FFresenius Kabi USA, LLC

Cancidas

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Neutropenia4 trials

Pediatric Patients2 trials

Candidiasis2 trials

Pneumonia1 trial

Infants1 trial

Acute Myeloid Leukemia1 trial

Invasive Fungal Infections1 trial

Aspergillosis1 trial

Stem Cell Transplant1 trial

Fungal Infection1 trial

Liver Transplant1 trial

Infections1 trial

Unspecified1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News